Clinical Trials on Dermatitis, Exfoliative

Total 3060 results

LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
Scotiaderm

Not yet recruiting

Efficacy of Cream for Moisture Associated Skin Damage From Fecal Incontinence and/or Diarrhea (Survey)

Incontinence-associated Dermatitis | Moisture Associated Skin Damage (MASD) (E.G., Incontinence-Associated Dermatitis [IAD], Perspiration, Drainage) | Fecal Incontinence Incontinence-associated Dermatitis
Vanda Pharmaceuticals

Completed

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Treatment-resistant Pruritus Associated With Atopic Dermatitis

Germany
University of Maryland, Baltimore
Integra LifeSciences Corporation

Completed

MediHoney for Radiation Dermatitis

Breast Cancer | Radiation Dermatitis

United States
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, France, Canada, Germany, Korea, Republic of, Taiwan, China
Sanofi

Recruiting

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO)

Dermatitis Atopic

Canada, United States
Centre Hospitalier Universitaire de la Réunion

Not yet recruiting

HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers (HypnoDA)

Dermatitis

Réunion
Sanofi

Recruiting

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

Dermatitis Atopic

Canada, United States, Australia, Bulgaria, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Hordinsky, Maria K., MD

Terminated

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Dermatitis

United States
Mayo Clinic

Active, not recruiting

Determining Molecular Drivers of Radiation Dermatitis

Breast Cancer

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

Dermatitis, Seborrheic
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
Sanofi

Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment (AD-BEASCUITS)

Dermatitis Atopic

Italy
Sanofi

Active, not recruiting

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Dermatitis Atopic

Australia, United States, Argentina, Brazil, Canada, Colombia, France, Mexico, Netherlands
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
DermaGen AB

Completed

A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060

Atopic Dermatitis

Sweden
Eli Lilly and Company

Not yet recruiting

Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Atopic Dermatitis

United States
Oneness Biotech Co., Ltd.

Not yet recruiting

Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.

Recruiting

A Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis

United States, Canada
AbbVie

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic Dermatitis

United States
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Atopic Dermatitis

Spain
Technoderma Medicines Inc.
Therapeutics, Inc.

Recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Not yet recruiting

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Eli Lilly and Company

Recruiting

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China, Korea, Republic of
Møreforsking AS
University of Manchester; Helse Møre og Romsdal HF; Epax Norway AS

Recruiting

Nutritional Study to Determine the Effect of Fish Oil on Atopic Dermatitis (CetoSkin)

Atopic Dermatitis

Norway
Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Akeso

Not yet recruiting

A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Akeso

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Atopic Dermatitis

China
Phoilex Ltd.
Phoenix Medical Spa X Peak Human

Recruiting

The Therapeutic Effects of Topical Cannabidiol (CBD) Products for Atopic Dermatitis

Atopic Dermatitis

Canada
Almirall, S.A.

Recruiting

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope)

Eczema | Atopic Dermatitis

Germany, Netherlands, United Kingdom
Mazandaran University of Medical Sciences

Recruiting

Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Iran, Islamic Republic of
Eli Lilly and Company

Recruiting

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, China, Canada, United States, Hungary, Mexico, Poland, Japan, Korea, Republic of
Amgen

Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Atopic Dermatitis

United States, Japan, Korea, Republic of, Australia, Taiwan, Spain, Switzerland, Germany, Croatia, Austria, Bulgaria, France, Denmark, China, Netherlands, Hungary, Czechia, Poland, Brazil, Greece, Portugal, Italy, Finland, Argentina, Sl... and more
Centre Hospitalier Universitaire de Nice

Recruiting

Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE)

Atopic Dermatitis

France
Numab Therapeutics AG
Kaken Pharmaceutical Co., Ltd.

Recruiting

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Atopic Dermatitis

Germany, Canada, United States, Poland
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response (DermAtOmics)

Atopic Dermatitis

Spain
Keymed Biosciences Co.Ltd

Recruiting

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Atopic Dermatitis

China
China Medical University Hospital

Recruiting

Vitamin D Treatment Effect for Atopic Dermatitis in Children

Atopic Dermatitis

Taiwan
CAGE Bio Inc.

Not yet recruiting

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Atopic Dermatitis
AbbVie

Recruiting

An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab (CAN UpTIMISE)

Atopic Dermatitis

Canada
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Dermatitis, Atopic

Korea, Republic of
Pfizer

Recruiting

A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Atopic Dermatitis

Japan
Peking University People's Hospital
Zhonghao Pharmaceutical

Recruiting

Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Abrocitinib) in Adult Patients With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Germany
Ribon Therapeutics, Inc.

Recruiting

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

Atopic Dermatitis

Australia, New Zealand
AbbVie

Recruiting

A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting (UP-TAINED)

Atopic Dermatitis

Germany

3

Subscribe